BPH Energy (ASX:BPH) has delivered an update for the December 2025 quarter, highlighting operational milestones across its core investments in oil and gas, medical technology, and clean energy.
The company's diversified strategy continues to gain momentum as its investee companies transition from technical development toward commercialization and regulatory approvals in major global markets.
BPH’s energy portfolio remains a focal point, particularly through its stake in Advent Energy.
The high-potential PEP-11 project offshore New South Wales is nearing a critical juncture, with a Federal Court hearing scheduled for February to review prior licensing decisions.
Simultaneously, Clean Hydrogen Technologies is advancing Stage 1 production plans for "turquoise hydrogen"—a process that converts natural gas into hydrogen and solid carbon.
CHT is currently finalising engineering designs for facilities in Louisiana and India to meet local regulatory specifications.
In the biotechnology sector, Cortical Dynamics is nearing technical completion of its BARM 2.0 system.
This next-generation monitor integrates EEG data with artificial intelligence to provide clinicians with real-time insights into patient consciousness during surgery.
Following technical finalisation, Cortical plans to initiate clinical trials in the US and the Netherlands.
At the time of reporting, BPH Energy's share price was $0.0090.